Syngene International Ltd is an integrated research, development, and manufacturing company that provides scientific services from early discovery to commercial supply. It strives to meet the needs of companies in sectors such as pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. The company operates its business through four divisions – discovery services, development services, manufacturing services, and dedicated centres. The discovery services division carries out early-stage research from target identification to delivery of drug candidates for further development. Its capabilities comprise chemistry, biology, safety assessment, and research informatics for small molecules, and recombinant deoxyribonucleic acid (DNA) engineering, cell line development, sequencing, and protein sciences for large molecules. The development services division takes drug candidates and offers services ranging from preclinical to clinical trials including drug substance, drug development, and associated services to demonstrate safety, tolerability and efficacy. This division focuses on the science and engineering aspects of polymeric materials and small molecules, working in areas such as biopolymers, specialty polymers, highly active monomers, and performance chemicals. The manufacturing services division offers commercial-scale manufacturing of small and large molecules. Syngene’s dedicated research and development centres focus on the development of products such as acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anaesthetics, and generic injectables.